Evidence map›Paper›PMID 41799962›Full record

ArticleBioactive materials2026

Spatiotemporal activation of unfolded protein response by combined sonodynamic therapy and proteasome inhibition with bortezomib-conjugated TiN nanoparticles.

Dan Yin, Xuan Wu, Jian-Li Chen, Ke An, Yini Fang, Hao-Ming Xiong, Li Wang, Chen Huang, Guo-Yuan Zhu, Liang Cheng and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Dan YinState Key Laboratory of Mechanism and Quality of Chinese Medicine & Faculty of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau SAR, 999078, China.
Xuan WuState Key Laboratory of Mechanism and Quality of Chinese Medicine & Faculty of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau SAR, 999078, China.
Jian-Li ChenState Key Laboratory of Mechanism and Quality of Chinese Medicine & Faculty of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau SAR, 999078, China.
Ke AnDepartment of Physics, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, 999077, China.
Yini FangDepartment of Physics, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, 999077, China.
Hao-Ming XiongState Key Laboratory of Mechanism and Quality of Chinese Medicine & Faculty of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau SAR, 999078, China.
Li WangInstitute of Functional Nano & Soft Materials (FUNSOM), Soochow University, Suzhou, 215123, China.
Chen HuangState Key Laboratory of Mechanism and Quality of Chinese Medicine & Faculty of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau SAR, 999078, China.
Guo-Yuan ZhuState Key Laboratory of Mechanism and Quality of Chinese Medicine & Faculty of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau SAR, 999078, China.
Liang ChengMacao Institute of Materials Science and Engineering, Macau University of Science and Technology, Taipa, Macau SAR, 999078, China.
Jianfang WangDepartment of Physics, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, 999077, China.
Xiao-Ming ZhuState Key Laboratory of Mechanism and Quality of Chinese Medicine & Faculty of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau SAR, 999078, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activation of unfolded protein response (UPR) has recently been identified as a new target for cancer therapy. However, pharmacological agents activating UPR have not been approved in clinical practice. In this study, spatiotemporally controllable UPR activation was realized by the combination of ultrasound (US)-triggered sonodynamic therapy (SDT) with titanium nitride (TiN) NPs and proteasome inhibitor bortezomib (BTZ). BTZ-conjugated TiN NPs were prepared by using a linker of carminic acid (CA)-functionalized bovine serum albumin (BSA). CA interacts with BTZ to form dynamic boronate ester bond enabling pH- and ultrasound-responsive drug release and thus overcoming the challenge of poor drug release for the conventional delivery systems. Compared with traditional sonosensitizer TiO

Indexed as

BortezomibProteasome inhibitorsReactive oxygen speciesSonodynamic therapyTitanium nitrideUnfolded protein response

Identifiers

PMID41799962
PMCPMC12964231

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.